 Vanessa Richardson
Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 3 | 2025 | 374 | 0.450 |
Why?
| | Mucociliary Clearance | 2 | 2021 | 44 | 0.320 |
Why?
| | Exercise | 3 | 2025 | 2198 | 0.280 |
Why?
| | Walking | 2 | 2025 | 542 | 0.190 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2022 | 203 | 0.170 |
Why?
| | Surgical Clearance | 1 | 2021 | 6 | 0.170 |
Why?
| | Erythrocyte Transfusion | 1 | 2023 | 225 | 0.160 |
Why?
| | Disulfides | 1 | 2021 | 94 | 0.160 |
Why?
| | Health Services for the Aged | 1 | 2021 | 73 | 0.160 |
Why?
| | Cystic Fibrosis | 2 | 2021 | 1161 | 0.160 |
Why?
| | Mucus | 1 | 2021 | 75 | 0.160 |
Why?
| | Exercise Therapy | 1 | 2025 | 475 | 0.160 |
Why?
| | Vascular Diseases | 1 | 2022 | 252 | 0.150 |
Why?
| | Physical Therapy Modalities | 1 | 2023 | 336 | 0.150 |
Why?
| | Geriatric Assessment | 1 | 2021 | 239 | 0.140 |
Why?
| | Mucin 5AC | 1 | 2018 | 71 | 0.140 |
Why?
| | Pseudomonas Infections | 1 | 2020 | 230 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2021 | 254 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2018 | 228 | 0.120 |
Why?
| | Inpatients | 1 | 2021 | 553 | 0.120 |
Why?
| | Lung | 4 | 2021 | 4106 | 0.110 |
Why?
| | Length of Stay | 1 | 2021 | 1349 | 0.110 |
Why?
| | Electronic Health Records | 1 | 2023 | 1196 | 0.110 |
Why?
| | Accelerometry | 2 | 2025 | 118 | 0.100 |
Why?
| | MicroRNAs | 1 | 2017 | 686 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2381 | 0.080 |
Why?
| | Sepsis | 1 | 2017 | 664 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2021 | 4560 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 1189 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2017 | 875 | 0.070 |
Why?
| | Respiratory Function Tests | 2 | 2021 | 544 | 0.070 |
Why?
| | Veterans | 3 | 2025 | 1635 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 2187 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2020 | 2588 | 0.060 |
Why?
| | Telemedicine | 2 | 2025 | 961 | 0.060 |
Why?
| | Humans | 12 | 2025 | 145474 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2664 | 0.050 |
Why?
| | Male | 8 | 2025 | 72842 | 0.050 |
Why?
| | Female | 8 | 2025 | 78844 | 0.050 |
Why?
| | Aged | 4 | 2025 | 26153 | 0.050 |
Why?
| | Ethics Committees, Research | 1 | 2023 | 41 | 0.050 |
Why?
| | Peroxynitrous Acid | 1 | 2022 | 11 | 0.050 |
Why?
| | Self-Management | 1 | 2024 | 202 | 0.040 |
Why?
| | Middle Aged | 4 | 2025 | 36215 | 0.040 |
Why?
| | Preliminary Data | 1 | 2021 | 10 | 0.040 |
Why?
| | Osteoarthritis, Knee | 1 | 2025 | 280 | 0.040 |
Why?
| | Expectorants | 1 | 2021 | 23 | 0.040 |
Why?
| | Recovery of Function | 1 | 2025 | 716 | 0.040 |
Why?
| | Respiration | 1 | 2021 | 206 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 497 | 0.040 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 88 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 351 | 0.040 |
Why?
| | Health Plan Implementation | 1 | 2021 | 141 | 0.040 |
Why?
| | Estrogens | 1 | 2022 | 367 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 198 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 8057 | 0.040 |
Why?
| | Menopause | 1 | 2022 | 326 | 0.040 |
Why?
| | Glycoproteins | 1 | 2021 | 354 | 0.040 |
Why?
| | Veterans Health | 1 | 2020 | 190 | 0.040 |
Why?
| | Health Behavior | 1 | 2024 | 789 | 0.040 |
Why?
| | Sputum | 1 | 2020 | 302 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 271 | 0.030 |
Why?
| | Patient Discharge | 1 | 2025 | 992 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1261 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2022 | 892 | 0.030 |
Why?
| | Neoplasms, Experimental | 1 | 2018 | 167 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 254 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1891 | 0.030 |
Why?
| | Erythrocytes | 1 | 2023 | 748 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 943 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1747 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 2021 | 778 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2022 | 956 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2022 | 1356 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1048 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2018 | 635 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1374 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 251 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 858 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2188 | 0.020 |
Why?
| | Animals | 3 | 2021 | 38030 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1295 | 0.020 |
Why?
| | Mice | 2 | 2021 | 18329 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1321 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 22529 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1399 | 0.020 |
Why?
| | Child | 2 | 2021 | 22707 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3124 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2769 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4316 | 0.020 |
Why?
| | Asthma | 1 | 2021 | 1797 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8333 | 0.020 |
Why?
| | Mutation | 1 | 2018 | 4075 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5983 | 0.010 |
Why?
| | Child, Preschool | 1 | 2021 | 11853 | 0.010 |
Why?
| | United States | 1 | 2021 | 16098 | 0.010 |
Why?
| | Adult | 1 | 2021 | 40777 | 0.010 |
Why?
|
|
Richardson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|